Lycorine Carbamate Derivatives for Reversing P-glycoprotein-Mediated Multidrug Resistance in Human Colon Adenocarcinoma Cells
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24032061 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Shirley A R Sancha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal. Hauptthemen laut MEDLINE: Amaryllidaceae Alkaloids, Adenocarcinoma, Colonic Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia, FEDER, Szeged Foundation for Cancer Research (Szegedi Rákkutatásért Alapítvány, Hungary).
Abstract (Originalsprache)
Multidrug resistance (MDR) is a major challenge in cancer chemotherapy. Aiming at generating a small library of anticancer compounds for overcoming MDR, lycorine (1), a major Amaryllidaceae alkaloid isolated from Pancratium maritimum, was derivatized. Thirty-one new compounds (2–32) were obtained by chemical transformation of the hydroxyl groups of lycorine into mono- and di-carbamates. Compounds 1–32 were evaluated as MDR reversers, through the rhodamine-123 accumulation assay by flow cytometry and chemosensitivity assays, in resistant human colon adenocarcinoma cancer cells (Colo 320), overexpressing P-glycoprotein (P-gp, ABCB1). Significant inhibition of P-gp efflux activity was observed for the di-carbamate derivatives, mainly those containing aromatic substituents, at non-cytotoxic concentrations. Compound 5, bearing a benzyl substituent, and compounds 9 and 25, with phenethyl moieties, were among the most active, exhibiting strong inhibition at 2 µM, being more active than verapamil at 10-fold higher concentration. In drug combination assays, most compounds were able to synergize doxorubicin. Moreover, some derivatives showed a selective antiproliferative effect toward resistant cells, having a collateral sensitivity effect. In the ATPase assay, selected compounds (2, 5, 9, 19, 25, and 26) were shown to behave as inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal.
- Department of Medical Microbiology, Albert Szent-Györgyi Health Center, Faculty of Medicine, University of Szeged, Semmelweis utca 6, 6725 Szeged, Hungary.
ORCID-Profile: Shirley A R Sancha, Nikoletta Szemerédi, Gabriella Spengler, Maria-José U Ferreira
Förderung
- Fundação para a Ciência e Tecnologia
- FEDER
- Szeged Foundation for Cancer Research (Szegedi Rákkutatásért Alapítvány, Hungary)
- János Bolyai Research Scholarship
Zitieren
APA
Sancha, S. A. R., Szemerédi, N., Spengler, G., & Ferreira, M. U. (2023). Lycorine Carbamate Derivatives for Reversing P-glycoprotein-Mediated Multidrug Resistance in Human Colon Adenocarcinoma Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032061
Vancouver
Sancha SAR, Szemerédi N, Spengler G, Ferreira MU. Lycorine Carbamate Derivatives for Reversing P-glycoprotein-Mediated Multidrug Resistance in Human Colon Adenocarcinoma Cells. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032061
BibTeX
@article{Sancha2023,
author = {Sancha, Shirley A R and Szemerédi, Nikoletta and Spengler, Gabriella and Ferreira, Maria-José U},
title = {Lycorine Carbamate Derivatives for Reversing P-glycoprotein-Mediated Multidrug Resistance in Human Colon Adenocarcinoma Cells},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24032061}
}
EUVIMED